Canadian Tm Bioscience introduced its Early Access Program to the market this week. The programme is designed to provide testing labs with pre-commercial access to the company's genetic tests.

Tm Bioscience, currently commercialising a menu of tests for the rapidly growing genetic testing market, will aim to provide hospitals, academic institutions and genetic testing centres with Tag-It genetic tests for evaluation purposes.

"The Early Access Program is a key feature of our customer-driven product development process and ensures that we deliver the most suitable and cost- effective products for the rapidly growing genetic testing market," said Greg Hines, president and CEO of Tm Bioscience.

The company's pre-commercial pipeline includes the Tag- It Cystic Fibrosis and Tag-It P450 Drug Metabolism product lines. In 2002 the company launched a series of Tag-It tests, based on the Tm Universal Array platform and operate on the Luminex xMAP system, for coagulation disorders.